Cellid, Co., Ltd. Logo

Cellid, Co., Ltd.

299660.KQ

(0.0)
Stock Price

5.430,00 KRW

-19.65% ROA

-29.1% ROE

-7.08x PER

Market Cap.

113.745.170.000,00 KRW

28.05% DER

0% Yield

-1133.52% NPM

Cellid, Co., Ltd. Stock Analysis

Cellid, Co., Ltd. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Cellid, Co., Ltd. Fundamental Stock Analysis
# Analysis Rating
1 ROE

Unidentified ROE

2 ROA

Unidentified ROA

3 PBV

Unidentified ROA

4 DER

Unidentified DER

5 Revenue Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

6 Net Profit Growth

This company's net profit has remained stagnant over the past five years, indicating a lack of growth and making it a less favorable investment option.

7 Assets Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

8 Graham Number

Unidentified Graham Number

9 Dividend Growth

The company's dividend growth has remained flat for the past three years, offering no indication of improved returns and making it a less advantageous investment opportunity.

10 Dividend

The company's lack of dividends in the past three years may concern investors seeking regular income.

11 Buffet Intrinsic Value

The company's stock presents a potential concern as it appears overvalued (0) by Warren Buffett's formula, indicating that its market price exceeds its estimated intrinsic value.

Cellid, Co., Ltd. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Cellid, Co., Ltd. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Sell
4 Stoch RSI Sell

Cellid, Co., Ltd. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Cellid, Co., Ltd. Revenue
Year Revenue Growth
2015 639.819.818
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 909.090.909 100%
2022 480.000.000 -89.39%
2023 0 0%
2023 0 0%
2024 2.396.875.376 100%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Cellid, Co., Ltd. Research and Development Expenses
Year Research and Development Expenses Growth
2015 1.125.788.937
2016 1.511.206.219 25.5%
2017 1.941.213.538 22.15%
2018 3.364.385.581 42.3%
2019 3.131.067.361 -7.45%
2020 3.016.879.127 -3.78%
2021 15.758.659.233 80.86%
2022 7.886.432.444 -99.82%
2023 7.116.272.000 -10.82%
2023 7.469.602.080 4.73%
2024 3.692.028.656 -102.32%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Cellid, Co., Ltd. General and Administrative Expenses
Year General and Administrative Expenses Growth
2015 0
2016 0 0%
2017 0 0%
2018 2.574.900 100%
2019 12.773.110 79.84%
2020 169.416.140 92.46%
2021 762.121.280 77.77%
2022 638.402.880 -19.38%
2023 14.094.640 -4429.4%
2023 629.604.190 97.76%
2024 12.462.588.000 94.95%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Cellid, Co., Ltd. EBITDA
Year EBITDA Growth
2015 -1.178.951.900
2016 -1.723.965.630 31.61%
2017 -2.281.902.440 24.45%
2018 -3.974.571.730 42.59%
2019 -4.570.294.400 13.03%
2020 -4.794.618.550 4.68%
2021 -19.401.554.380 75.29%
2022 -12.311.259.760 -57.59%
2023 -11.473.944.400 -7.3%
2023 -12.306.062.630 6.76%
2024 -11.133.311.280 -10.53%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Cellid, Co., Ltd. Gross Profit
Year Gross Profit Growth
2015 639.819.818
2016 -64.845.066 1086.69%
2017 -69.812.022 7.11%
2018 -76.540.286 8.79%
2019 -109.509.149 30.11%
2020 -491.997.034 77.74%
2021 -1.378.937.430 64.32%
2022 -2.378.579.554 42.03%
2023 -6.768.000 -35044.5%
2023 -2.663.582.007 99.75%
2024 -3.231.167.212 17.57%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Cellid, Co., Ltd. Net Profit
Year Net Profit Growth
2015 -1.125.020.075
2016 -1.771.574.800 36.5%
2017 -5.408.291.932 67.24%
2018 -11.286.320.640 52.08%
2019 -2.493.555.414 -352.62%
2020 -4.125.998.488 39.56%
2021 -13.070.514.497 68.43%
2022 -22.864.575.136 42.84%
2023 -14.434.019.560 -58.41%
2023 -11.611.435.383 -24.31%
2024 -10.451.222.880 -11.1%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Cellid, Co., Ltd. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2015 -109
2016 -154 29.41%
2017 -469 67.38%
2018 -980 52.09%
2019 -242 -304.55%
2020 -390 37.79%
2021 -1.226 68.27%
2022 -2.141 42.74%
2023 -1.483 -44.37%
2023 -1.078 -37.57%
2024 -768 -40.36%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Cellid, Co., Ltd. Free Cashflow
Year Free Cashflow Growth
2015 -804.196.658
2016 -1.629.726.540 50.65%
2017 -1.391.218.025 -17.14%
2018 -7.811.553.659 82.19%
2019 -6.204.570.013 -25.9%
2020 -15.478.607.587 59.92%
2021 -11.317.983.614 -36.76%
2022 -13.418.987.444 15.66%
2023 -18.526.340.573 27.57%
2024 -5.354.158.338 -246.02%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Cellid, Co., Ltd. Operating Cashflow
Year Operating Cashflow Growth
2015 -627.734.785
2016 -1.503.756.540 58.26%
2017 -1.371.618.025 -9.63%
2018 -1.993.554.889 31.2%
2019 -1.920.789.391 -3.79%
2020 -3.763.479.965 48.96%
2021 -8.206.257.337 54.14%
2022 -12.216.037.230 32.82%
2023 -7.115.155.704 -71.69%
2024 -2.562.750.639 -177.64%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Cellid, Co., Ltd. Capital Expenditure
Year Capital Expenditure Growth
2015 176.461.873
2016 125.970.000 -40.08%
2017 19.600.000 -542.7%
2018 5.817.998.770 99.66%
2019 4.283.780.622 -35.81%
2020 11.715.127.622 63.43%
2021 3.111.726.277 -276.48%
2022 1.202.950.214 -158.67%
2023 11.411.184.869 89.46%
2024 2.791.407.699 -308.8%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Cellid, Co., Ltd. Equity
Year Equity Growth
2015 961.381.672
2016 -205.826.205 567.08%
2017 -5.527.521.037 96.28%
2018 13.495.505.111 140.96%
2019 51.329.625.149 73.71%
2020 47.295.782.651 -8.53%
2021 38.760.570.381 -22.02%
2022 22.438.888.800 -72.74%
2023 40.495.260.881 44.59%
2023 15.424.293.270 -162.54%
2024 34.758.216.488 55.62%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Cellid, Co., Ltd. Assets
Year Assets Growth
2015 2.833.613.863
2016 3.808.101.542 25.59%
2017 4.963.151.186 23.27%
2018 14.216.133.184 65.09%
2019 52.515.665.088 72.93%
2020 49.399.939.689 -6.31%
2021 58.256.319.253 15.2%
2022 45.857.390.754 -27.04%
2023 63.922.241.987 28.26%
2023 31.045.450.750 -105.9%
2024 53.698.889.521 42.19%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Cellid, Co., Ltd. Liabilities
Year Liabilities Growth
2015 1.872.232.191
2016 4.013.927.747 53.36%
2017 10.490.672.223 61.74%
2018 720.628.073 -1355.77%
2019 1.186.039.939 39.24%
2020 2.104.157.037 43.63%
2021 19.495.748.872 89.21%
2022 23.418.501.954 16.75%
2023 23.426.981.106 0.04%
2023 15.621.157.480 -49.97%
2024 18.940.673.033 17.53%

Cellid, Co., Ltd. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
67.21
Net Income per Share
-761.78
Price to Earning Ratio
-7.08x
Price To Sales Ratio
124.42x
POCF Ratio
-8.76
PFCF Ratio
-4.58
Price to Book Ratio
2.11
EV to Sales
134.91
EV Over EBITDA
-12.18
EV to Operating CashFlow
-14.73
EV to FreeCashFlow
-4.97
Earnings Yield
-0.14
FreeCashFlow Yield
-0.22
Market Cap
113,75 Bil.
Enterprise Value
123,33 Bil.
Graham Number
6617.88
Graham NetNet
-1307.64

Income Statement Metrics

Net Income per Share
-761.78
Income Quality
0.81
ROE
-0.29
Return On Assets
-0.19
Return On Capital Employed
-0.25
Net Income per EBT
1
EBT Per Ebit
0.81
Ebit per Revenue
-14.01
Effective Tax Rate
0

Margins

Sales, General, & Administrative to Revenue
6.55
Research & Developement to Revenue
5.38
Stock Based Compensation to Revenue
0.42
Gross Profit Margin
-2.92
Operating Profit Margin
-14.01
Pretax Profit Margin
-11.34
Net Profit Margin
-11.34

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-615.46
Free CashFlow per Share
-1823.9
Capex to Operating CashFlow
-1.96
Capex to Revenue
17.98
Capex to Depreciation
6.14
Return on Invested Capital
-0.29
Return on Tangible Assets
-0.2
Days Sales Outstanding
479.82
Days Payables Outstanding
42.55
Days of Inventory on Hand
18.34
Receivables Turnover
0.76
Payables Turnover
8.58
Inventory Turnover
19.9
Capex per Share
1208.44

Balance Sheet

Cash per Share
11,87
Book Value per Share
2.555,19
Tangible Book Value per Share
2484.8
Shareholders Equity per Share
2555.19
Interest Debt per Share
787.76
Debt to Equity
0.28
Debt to Assets
0.18
Net Debt to EBITDA
-0.95
Current Ratio
0.62
Tangible Asset Value
33,80 Bil.
Net Current Asset Value
-17,20 Bil.
Invested Capital
42076098980
Working Capital
-1,06 Bil.
Intangibles to Total Assets
0.02
Average Receivables
1,19 Bil.
Average Payables
0,28 Bil.
Average Inventory
154043554.5
Debt to Market Cap
0.09

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Cellid, Co., Ltd. Dividends
Year Dividends Growth
2022 0

Cellid, Co., Ltd. Profile

About Cellid, Co., Ltd.

Cellid, Inc. develops immunothetherapeutic vaccines for cancer and/or infectious diseases therapies. It is developing BVAC-C for cervical, head and neck, anal, and genital cancer with human papilloma virus antigen; BVAC-B for gastric, ovarian, lung, and pancreatic cancer with HER-2/neu antigen; and BVAC-P for prostate, urinary tract, and brain cancer with PAP/PSMA antigens. The company is also developing BVAC-M for cancers, such as melanoma with GP100/MAGE-A3 antigens; and BVAC-Neo, a customized immunotherapeutic vaccine. Cellid, Inc. was founded in 2006 and is based in Seoul, South Korea.

CEO
Yuil Kang Chang
Employee
64
Address
Building 142, Korea Seoul National University
Seoul, 08826

Cellid, Co., Ltd. Executives & BODs

Cellid, Co., Ltd. Executives & BODs
# Name Age
1 Kim Minsoo
In charge of Finance/IR(Management Support Office) & Director
70
2 Han BeomSoo
Head of GMP Engineering & Director
70
3 Yuil Kang Chang
Chief Executive Officer & Representative Director
70
4 Kim Yookyung
Head of GMP Production Division & Director
70

Cellid, Co., Ltd. Competitors

ABL Bio Inc. Logo
ABL Bio Inc.

298380.KQ

(0.0)
ALTEOGEN Inc. Logo
ALTEOGEN Inc.

196170.KQ

(0.0)
Kmw Inc. Logo
Kmw Inc.

032500.KQ

(0.0)
Celltrion Pharm, Inc. Logo
Celltrion Pharm, Inc.

068760.KQ

(0.0)
SK Inc. Logo
SK Inc.

034730.KS

(2.0)